What is King Pharmaceuticals's all other lines — year 8?

King Pharmaceuticals (KG) reported all other lines — year 8 of 0.1% in Q4 2025.

What does all other lines — year 8 mean?

This metric measures the financial performance of secondary business lines and non-core segments during the eighth fiscal year. It consolidates data from various activities that do not fit into the primary reporting segments of the company. Tracking this metric is essential for assessing the impact of peripheral business units on the overall financial health of the organization.

King Pharmaceuticals KG All other lines — Year 8

Other product segments

General Liability

6.4%—

European Hospital Liability

5%—

Commercial Auto Liability

2.3%—

International

-0.1%—

Similar metrics at other companies

GLREFinancial — Year 8

0.6%—

ACGLMulti-line and other specialty — Year Eight

1.4%+0.3pp

SPNTOther — Year 10

0%—

SKWDMulti-line Solutions — Year 8

2.4%+1.1pp

GLREMultiline — Year 8

0.6%+0.2pp

SPNTOther Specialties — Year 8

0.3%-0.4pp

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearEight.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's all other lines — year 8.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's all other lines — year 8?: King Pharmaceuticals (KG) reported all other lines — year 8 of 0.1% in Q4 2025.
What does all other lines — year 8 mean?: This metric measures the financial performance of secondary business lines and non-core segments during the eighth fiscal year. It consolidates data from various activities that do not fit into the primary reporting segments of the company. Tracking this metric is essential for assessing the impact of peripheral business units on the overall financial health of the organization.